Analysts predict that Johnson & Johnson (NYSE:JNJ) will announce $20.25 billion in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $20.01 billion and the highest is $20.43 billion. Johnson & Johnson reported sales of $18.84 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 7.5%. The firm is scheduled to report its next quarterly earnings results before the market opens on Tuesday, July 17th.
According to Zacks, analysts expect that Johnson & Johnson will report full year sales of $81.55 billion for the current year, with estimates ranging from $81.41 billion to $81.82 billion. For the next year, analysts forecast that the company will post sales of $84.50 billion per share, with estimates ranging from $83.04 billion to $86.26 billion. Zacks’ sales calculations are an average based on a survey of research analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The firm had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. During the same period in the prior year, the company posted $1.83 EPS. The company’s revenue was up 12.6% on a year-over-year basis.
A number of equities research analysts have recently commented on JNJ shares. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, April 9th. Jefferies Financial Group set a $153.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, April 13th. Vetr lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price objective on the stock. in a research note on Monday, March 26th. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Finally, Goldman Sachs Group set a $134.00 price objective on shares of Johnson & Johnson and gave the company a “sell” rating in a research note on Tuesday, April 17th. Six analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $141.60.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Avalon Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.3% in the first quarter. Avalon Advisors LLC now owns 284,681 shares of the company’s stock valued at $36,481,000 after buying an additional 3,720 shares in the last quarter. Mount Yale Investment Advisors LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at $1,566,000. Greenline Partners LLC lifted its stake in shares of Johnson & Johnson by 16.8% in the first quarter. Greenline Partners LLC now owns 61,708 shares of the company’s stock valued at $7,908,000 after buying an additional 8,892 shares in the last quarter. Allianz Life Insurance Co of North America bought a new position in shares of Johnson & Johnson in the first quarter valued at $458,000. Finally, Rikoon Group LLC lifted its stake in shares of Johnson & Johnson by 1.3% in the first quarter. Rikoon Group LLC now owns 96,278 shares of the company’s stock valued at $11,992,000 after buying an additional 1,255 shares in the last quarter. 65.97% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:JNJ traded down $0.74 during trading on Friday, reaching $121.61. The stock had a trading volume of 5,666,040 shares, compared to its average volume of 7,401,458. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The firm has a market cap of $328.90 billion, a P/E ratio of 16.66, a P/E/G ratio of 1.88 and a beta of 0.73.
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th were paid a dividend of $0.90 per share. The ex-dividend date of this dividend was Friday, May 25th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a yield of 2.96%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.